
Monday’s health summary covers a large study comparing GLP-1 drugs with metformin in people with prediabetes, a record outbreak of hand, foot and mouth disease in Ho Chi Minh City, the rising Ebola toll in Congo, new WHO targets for injectable tuberculosis treatments and the certification of Barbados for ending mother-to-child HIV transmission.
GLP-1 drugs outperform metformin at preventing diabetes in adults with prediabetes, study finds
Researchers who examined the medical records of over 250,000 obese adults with prediabetes found that those taking GLP-1 drugs were about 1.5 times more likely to bring their blood sugar back to normal than those on metformin, the standard medicine for preventing type 2 diabetes. They also had a 31% lower risk of developing the disease and a 41% lower risk of dying from any cause over five years, according to the preliminary research, which will be presented at an American Heart Association meeting in Chicago.
People on the GLP-1 drugs semaglutide, tirzepatide, liraglutide or dulaglutide also had 15% fewer heart attacks and 20% fewer strokes, while heart failure was 25% less common and atrial fibrillation 8% less common. The study author, Vinicius de Sousa Barzon Serra of the Mayo Clinic in Arizona, said metformin remained a safe, cheap first choice and that the findings were about discussing more options with some patients. The abstract has not been peer-reviewed. Nearly 40% of US adults have prediabetes, the association said.
GLP-1 receptor agonists are a class of drugs that lower blood sugar and reduce appetite by copying the action of a hormone released in the small intestine. They were first developed to treat type 2 diabetes, and some have since been approved for obesity, including the injections sold as Wegovy, Zepbound and Saxenda. A pill form of semaglutide was approved in the United States in December 2025 and entered mass production in January 2026. The drugs are also being studied for liver disease and addictions.
Hand, foot and mouth disease cases in Ho Chi Minh City reach 44,191 as a severe strain circulates
Ho Chi Minh City has recorded 44,191 cases of hand, foot and mouth disease so far in 2026, more than 25 per cent above its total for the whole of 2025, health officials said. The city’s disease control centre reported 1,850 new cases in a single week in October and said 60 samples had tested positive for enterovirus 71, the strain most linked to fatal brain complications in young children, a sign that it is now circulating widely. A newly approved vaccine protects only against that strain.
The city ended 2025 with about 35,440 cases, a figure passed this year with at least two months to go, and its hospitals are also treating severe cases sent from other southern provinces. Across Vietnam there were about 100,000 cases between January and September, more than 2.5 times the figure for the same period last year, and children under five account for about 87 per cent of them. Dr Nguyen Minh Tien of the city’s Children’s Hospital said delays in transferring severe cases could cost the chance of treatment.
Hand, foot and mouth disease is a common infection caused by a group of enteroviruses, usually starting with fever and followed by spots or blisters on the hands, feet and mouth. Symptoms appear 3 to 6 days after exposure, and most people recover on their own in 7 to 10 days. It spreads through close contact, coughing and faeces, mostly affects children under five and often occurs in small outbreaks in nurseries. Large outbreaks have been recorded in Asia since 1997.
Ebola deaths in Congo pass 5,000 as health workers strike over unpaid wages
Congo’s Ministry of Health said on Saturday that the Ebola outbreak in the country had killed 5,026 of the 10,351 people infected, a death rate of nearly 50%. Patrick Otim of the World Health Organization called it a tragic milestone and said one-third of those who died had never reached a treatment centre. The outbreak, declared in mid-May, has spread to 67 of the country’s 178 health zones, and the Africa Centres for Disease Control said about 80% of new cases come from outside known chains of contacts.
Most cases are in the eastern provinces of Ituri and North Kivu, where conflict with armed groups and distrust among residents have hampered the response, and a nurse was killed while answering an alert last week. Workers at a treatment centre in Tchomia went on strike on Friday to demand four months of unpaid wages, and officials in Beni said a lack of fuel and money had halted services. Kenya has confirmed eight cases and 2 deaths, and Nigeria’s only confirmed patient was evacuated to Switzerland.
The outbreak is caused by the Bundibugyo virus, a close relative of the Zaire ebolavirus that causes a haemorrhagic fever and has no known vaccine or specific treatment. The virus is named after Bundibugyo in western Uganda, where it was first identified, and it also caused outbreaks in 2007 and 2012. The current epidemic is the second deadliest Ebola outbreak on record, after the West African epidemic between 2014 and 2016, which killed 11,000 people across several countries.
WHO sets targets for long-acting tuberculosis injections
The World Health Organization has published target profiles describing what long-acting injectable medicines for preventing and treating tuberculosis must achieve to be useful in practice. For preventive treatment, the aim is a full course given as a single injection in one visit, while for active disease the goal is treatment lasting four months at most, delivered over a maximum of three visits. Both profiles call for small injection volumes, no need for refrigerated transport and results at least as good as current pills.
Tereza Kasaeva, who directs the WHO department for HIV, tuberculosis, hepatitis and sexually transmitted infections, said the injections could make prevention and treatment much simpler and that the profiles tell developers early what a new regimen must deliver. The documents set a minimum and an optimal requirement for each feature and cover trial design, access and pricing. They were drawn up by an expert group after a public consultation in April and May 2026, and the WHO said work on better oral regimens should continue.
Tuberculosis is still treated mainly with daily pills taken over months, which many patients find hard to sustain. The standard course for active disease combines isoniazid, rifampicin, pyrazinamide and ethambutol for the first two months, followed by isoniazid and rifampicin for four more, and patients are expected to be clear of the bacteria after six months. Latent infection is treated with three to nine months of isoniazid alone, or a shorter combination with rifampicin that carries less risk of liver damage.
WHO certifies that Barbados has eliminated mother-to-child transmission of HIV
The World Health Organization has certified Barbados for ending the passing of HIV from mothers to their babies as a public health problem, after an independent assessment found that no infants born there were infected this way from 2022 to 2024. Over those three years, antenatal care, HIV testing and antiretroviral treatment for expectant mothers with the virus each reached 98% coverage. WHO Director-General Tedros Adhanom Ghebreyesus said the island offered free services to every pregnant woman regardless of nationality.
Barbados joins 26 countries and territories recognised by the WHO for eliminating or being on track to eliminate mother-to-child transmission of HIV, syphilis or hepatitis B, 15 of them in the Americas. Health Minister Lisa Cummins said the result would allow the country’s children to live full lives. Testing and treatment are free and confidential, and one public hospital handles about 93% of births. Earlier certifications in the region included the Bahamas and Turks and Caicos in 2026, Brazil in 2025 and Jamaica in 2024.
A vertically transmitted infection passes directly from a mother to her baby during pregnancy or childbirth, and HIV is one of several viruses and bacteria that can spread in this way, along with syphilis, hepatitis B, rubella and others. HIV is mostly spread by other routes, but medicine has sharply reduced transmission from mothers to children. In the United States, perinatal HIV cases fell after the introduction of counselling, voluntary testing and the use of the antiretroviral drug zidovudine.